Diseases
Researchers from the University of Cambridge have made a breakthrough in the treatment of Alzheimer's Disease by employing an AI-guided tool to enhance precision in patient stratification. The study, published in Nature Communications, analyzed data from the AMARANTH trial of lanabecestat, a BACE1 inhibitor, and found that the
Diseases
Research conducted at the University of Oxford has shed light on the effectiveness of vasodilatory drugs in treating small vessel disease, a condition affecting blood flow to the brain. The study, led by Karolina Feakins and colleagues, aimed to identify the most sensitive physiological markers of treatment response to sildenafil,
Diseases
The Graves disease pipeline constitutes 8+ key companies working towards developing 10+ treatment therapies, offering new hope for patients suffering from this autoimmune disorder. The pipeline report covers a comprehensive analysis of the present clinical development scenario and growth prospects across the Graves disease market. Key companies involved in the
Clinical trials
New research from Sahlgrenska University Hospital in Gothenburg, Sweden, has raised concerns about the effectiveness of time-lapse imaging (TLI) systems in improving in vitro fertilization (IVF) outcomes. Despite significant investment by IVF clinics, the technology has shown inconsistent results, leading to uncertainty about its benefits. The study, published in BMJ
Diseases
Sjögren's disease is a chronic, disabling autoimmune disease affecting approximately 0.25% of the population, with an estimated 50% of patients undiagnosed. Novartis has announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the
Cancer research
According to a recent study published in JAMA Network Open, researchers from the Duke Cancer Institute have made new discoveries regarding the treatment of metastatic hormone-sensitive prostate cancer. The study, which analyzed data from the ARCHES randomized clinical trial, found that men with prostate cancer who received enzalutamide plus androgen
Cancer research
A major new cancer vaccine trial will be led by the Clatterbridge Cancer Centre in Liverpool, a leading hospital in the UK, in partnership with 14 research hospitals across the country. The trial is part of the National Health Service's (NHS) world-leading "matchmaking" service, the Cancer
Cancer research
Asan Medical Center, a major hospital in South Korea, has registered a clinical trial with the Clinical Research Information Service (CRiS) for the development of a patient-tailored prostate cancer diagnostic protocol using magnetic resonance imaging (MRI) and biomarkers. The study aims to reduce unnecessary biopsies, enhance high-risk prostate cancer detection,
Cancer research
Shanghai Pudong Hospital has listed a Phase 2 clinical trial for patients with MSS/pMMR colorectal cancer, a type of cancer that has failed first-line treatment. The trial involves a collaboration with Shanghai Junshi Bioscience Co., Ltd. and will enroll 32 patients from the USA. The trial aims to assess
Cancer research
Researchers at the Case Comprehensive Cancer Center are conducting a Phase 2 clinical trial to investigate the effectiveness of pulmonary rehabilitation for advanced lung cancer survivors. The study aims to recruit 85 participants from the USA and involve collaboration with the United States Department of Defense. The trial has two
Cancer research
Researchers at the University of Oklahoma have initiated a Phase 2 clinical trial to study the combination of varenicline and nicotine lozenges, along with a smartphone medication adherence intervention, to promote smoking cessation. The trial aims to recruit 496 participants from the USA and will evaluate the effectiveness of this
Cancer research
Researchers from the Dana-Farber Cancer Institute have made significant strides in cancer immunotherapy, presenting a novel biomaterial-based vaccine that shows potential in treating metastatic melanoma. The innovative vaccine, known as WDVAX, has been tested in a phase I clinical trial and has demonstrated the ability to induce immune activation in
